Ewing's sarcoma oncoprotein EWS-FLI1: The perfect target without a therapeutic agent

Future Oncology

Volumn 1, Issue 4, 2005, Pages 521-528

  Üren, Aykut ^a   Toretsky, Jeffrey A ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromosomal translocation; Ewings sarcoma; EWSFLI1; highthroughput screening; molecular targeting; recombinant proteins; transcriptional control

Indexed keywords

EWS FLI1 FUSION PROTEIN; EWS-FLI1 FUSION PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR FLI 1;

ADOLESCENT; ADULT; ANIMAL; BONE TUMOR; CHILD; EWING SARCOMA; GENE TRANSLOCATION; GENETICS; HUMAN; PRESCHOOL CHILD; REVIEW;

ADOLESCENT; ADULT; ANIMALS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; HUMANS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; SARCOMA, EWING'S; TRANSLOCATION, GENETIC;

EID: 33744502102     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.4.521     Document Type: Review

References (48)

1. Arnd CA, Crist WM: Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 341(5), 342-352 (1999
2. Grier HE, Krailo MD, Tarbell NJ et al.: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitisve neuroectodermal tumor of bone. N. Engl. J. Med. 348(8), 694-701 (2003
3. Zoubek A, Dockhorn-Dworniczak B, Delattre O et al.: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewings tumor patients? J. Clin. Oncol. 14(4), 1245-1251 (1996
4. de Alava E, Kawai A, Healey JH et al.: EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 16(4), 1248-1255 (1998
5. Toretsky JA, Connell Y, Neckers L, Bhat NK: Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J. Neurooncol. 31(1-2), 9-16 (1997
6. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y: EWS-FLI1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor. J. Clin. Invest. 99(2), 239-247 (1997
7. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES: Loss of tumorigenicity of Ewings sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 11(6), 1049-1054 (1995
8. Maksimenko A, Malvy C, Lambert G et al.: Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies. Pharm. Res. 20(10), 1565-1567 (2003
9. Kovar H, Aryee DN, Jug G et al.: FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 7(4), 429-437 (1996
10. Kovar H, Ban J, Pospisilova S: Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin. Cancer Biol. 13(4), 275-281 (2003
11. Dohjima T, Lee NS, Li H, Ohno T, Rossi JJ: Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther. 7(6), 811-816 (2003
12. Chansky HA, Barahmand-Pour F, Mei Q et al.: Targeting of EWS/FLI1 by RNA interference attenuates the tumor phenotype of Ewings sarcoma cells in vitro. J. Orthop. Res. 22(4), 910-917 (2004
13. Lambert G, Bertrand JR, Fattal E et al.: EWS fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279(2), 401-406 (2000
14. Chan D, Wilson TJ, Xu D et al.: Transformation induced by Ewings sarcoma associated EWS/FLI-1 is suppressed by KRAB/FLI-1. Br. J. Cancer 88(1), 137-145 (2003
15. May WA, Gishinzky ML, Lessnick SL et al.: Ewings sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl Acad. Sci. USA 90(12), 5752-5756 (1993
16. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H: Oncogenic EWS-FLI1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17(5), 603-610 (1998
17. Matsui Y, Chansky HA, Barahmand-Pour F et al.: COL11A2 collagen gene transcription is differentially regulated by EWS/ERG sarcoma fusion protein and wild-type ERG. J. Biol. Chem. 278(13), 11369-11375 (2003
18. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT: Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol. Cell. Biol. 15(8), 4623-4630 (1995
19. Khan J, Wei JS, Ringner M et al.: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Med. 7(6), 673-679 (2001
20. Baer C, Nees M, Breit S et al.: Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int. J. Cancer 110(5), 687-694 (2004
21. Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA: PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's sarcoma tumorigenesis. Oncogene 24, 2715-2722 (2005
22. Nishimori H, Sasaki Y, Yoshida K et al.: The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 21(54), 8302-8309 (2002
23. Fukuma M, Okita H, Hata J, Umezawa A: Up-regulation of Id2, an oncogenic helixloop-helix protein, is mediated by the chimeric EWS/ets protein in Ewings sarcoma. Oncogene 22(1), 1-9 (2003
24. Nakatani F, Tanaka K, Sakimura R: Identification of p21WAF1/CIP1 as a direct target of EWS-FLI1 oncogenic fusion protein. J. Biol. Chem. 278(17), 15105-15115 (2003
25. Siligan C, Ban J, Bachmaier R et al.: EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 24(15), 2512-2524 (2005
26. Prieur A, Tirode F, Cohen P, Delattre O: EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24(16), 7275-7283 (2004
27. Hahm KB, Cho K, Lee C et al.: Repression of the gene encoding the TGF-βtype II receptor is a major target of the EWS-FLI1 oncoprotein. Nature Genet. 23(2), 222-227 (1999
28. Welford SM, Hebert SP, Deneen B, Arvand A, Denny CT: DNA binding domainindependent pathways are involved in EWS/FLI1-mediated oncogenesis. J. Biol. Chem. 276(45), 41977-41984 (2001
29. Knoop LL, Baker SJ: The splicing factor U1C represses EWS/FLI-mediated transactivation. J. Biol. Chem. 275(32), 24865-24871 (2000
30. Helman LJ, Meltzer P: Mechanisms of sarcoma development. Nature Rev. Cancer 3(9), 685-694 (2003
31. Uren A, Tcherkasskaya O, Toretsky JA: Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry 43(42), 13579-13589 (2004
32. Yin X, Giap C, Lazo JS, Prochownik EV: Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22(40), 6151-6159 (2003
33. Zwerner JP, Guimbellot J, May WA: EWS/FLI function varies in different cellular backgrounds. Exp. Cell. Res. 290(2), 414-419 (2003
34. Torchia EC, Jaishankar S, Baker SJ: Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res. 63(13), 3464-3468 (2003
35. Rorie CJ, Thomas VD, Chen P et al.: The EWS/FLI-1 fusion gene switches the differentiation program of neuroblastomas to Ewings sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 64(4), 1266-1277 (2004
36. Eliazer S, Spencer J, Ye D, Olson E, Ilaria RL Jr: Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol. Cell. Biol. 23(2), 482-492 (2003
37. Forster A, Pannell R, Drynan LF et al.: The invertor knock-in conditional chromosomal translocation mimic. Nature Methods 2(1), 27-30 (2005
38. Morra M, Lu J, Poy F et al.: Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J. 20(21), 5840-5852 (2001
39. Sidorenko SP, Clark EA: The dual-function CD150 receptor subfamily: the viral attraction. Nature Immunol. 4(1), 19-24 (2003
40. Thompson AD, Braun BS, Arvand A et al.: EAT-2 is a novel SH2 domain containing protein that is up-regulated by Ewings sarcoma EWS/FLI1 fusion gene. Oncogene 13(12), 2649-2658 (1996
41. Arvand A, Bastians H, Welford SM: EWS/FLI1 up-regulates mE2-C, a cyclinselective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 17(16), 2039-2045 (1998
42. May WA, Arvand A, Thompson AD et al.: EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nature Genet. 17(4), 495-497 (1997
43. Bailly RA, Bosselut R, Zucman J et al.: DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewings sarcoma. Mol. Cell. Biol. 14(5), 3230-3241 (1994
44. Zwerner JP, May WA: PDGF-C is an EWS/FLI induced transforming growth factor in Ewings family tumors. Oncogene 20(5), 626-633 (2001
45. Dauphinot L, De Oliveira C, Melot T et al.: Analysis of the expression of cell cycle regulators in Ewings cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20(25), 3258-3265 (2001
46. Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT: PIM3 protooncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol. Cell. Biol. 23(11), 3897-3908 (2003
47. Watanabe G, Nishimori H, Irifune H et al.: Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Genes Chromosomes Cancer 36(3), 224-232 (2003
48. www.emedicine.com/ped/topic2589.htm Toretsky JA: Ewings sarcoma and primitive neuroectodermal tumors (2003). (Accessed July 2005)